RxDoctor Payments Data

Christina Lynch

Nurse Practitioner · Valrico, FLNPI 1225578008

Payments from drug & device makers

$7,401in general payments, 2019–2025

Across 434 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$906
  • Pfizer$864
  • GSK$486
  • AstraZeneca$461
  • Lilly USA, LLC$412
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$7,376100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,401 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$63,475
Medicare patients
239
Services billed
1,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$75,118
RybelsusSemaglutide18$49,629
FarxigaDapagliflozin Propanediol48$48,787
EliquisApixaban24$35,581
JardianceEmpagliflozin21$24,806
MounjaroTirzepatide15$15,884
TrulicityDulaglutide11$14,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,762
Tresiba Flextouch U-100Insulin Degludec13$8,352
SymbicortBudesonide/Formoterol Fumarate19$6,245
Rosuvastatin Calcium219$2,684
SynthroidLevothyroxine Sodium18$1,845
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,794
Gabapentin121$1,638
Duloxetine Hcl64$1,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,102$124,74789 claims
AstraZenecaFarxiga, Symbicort$461$55,03267 claims
PfizerEliquis$864$35,58124 claims
Lilly USA, LLCMounjaro, Trulicity$412$30,29126 claims
Boehringer IngelheimJardiance$93$24,80621 claims
GSKTrelegy Ellipta$486$12,76214 claims
AbbVieSynthroid$906$1,84518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Valrico

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →